Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients

<b>Background</b>: Atopic dermatitis (AD) is an inflammatory skin disease characterized by a wide phenotypic variety with a very complex pathophysiological mechanism that has led to the identification of new therapeutic targets, such as janus kinasis (JAK) inhibitors. <b>Objectives...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Giulia Radi, Oriana Simonetti, Giulio Rizzetto, Federico Diotallevi, Elisa Molinelli, Annamaria Offidani
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
atopic dermatitis
baricitinib
JAK inhibitors
efficacy
safety
Medicine
R
Acceso en línea:https://doaj.org/article/5c029ab8ce6f4339b211259eed29fb6f
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares